Avandia Retaining Preferred Status On 2008 Part D Formularies – For Now
Executive Summary
So far GlaxoSmithKline's Avandia (rosiglitazone) appears to be retaining its tier 2 status on the 2008 formularies of major Medicare Part D plans despite safety concerns that surfaced earlier this year
You may also be interested in...
Fosamax Formulary Analysis: Health Plans Shift Tiers Or Delete Brand
A number of major health insurers are in the process of moving Merck's Fosamax (alendronate) to higher cost-sharing tiers or off formularies altogether following the recent launch of generic competitors
Drug Reimbursement In Brief From Pharma Earnings Calls
Formulary access for Lipitor: "Our access remains in the range of 65 to 70 [percent] at tier 2 across commercial and Medicare lives," Pfizer Worldwide Pharmaceutical Operations President Ian Read commented during the firm's third quarter earnings call Oct. 18. Noting that U.S. prescriptions for the cholesterol reducer were down about 13 percent compared to 2006, he pointed out that losses from patient switches to generics have "stabilized" and the product's new patient volume is "fluctuating at around a 20 percent share." Lipitor's third quarter revenues declined 3 percent to $3.2 billion versus the comparable 2006 quarter...
Drug Reimbursement In Brief From Pharma Earnings Calls
Formulary access for Lipitor: "Our access remains in the range of 65 to 70 [percent] at tier 2 across commercial and Medicare lives," Pfizer Worldwide Pharmaceutical Operations President Ian Read commented during the firm's third quarter earnings call Oct. 18. Noting that U.S. prescriptions for the cholesterol reducer were down about 13 percent compared to 2006, he pointed out that losses from patient switches to generics have "stabilized" and the product's new patient volume is "fluctuating at around a 20 percent share." Lipitor's third quarter revenues declined 3 percent to $3.2 billion versus the comparable 2006 quarter...